Therapeutic innovation is moving beyond conventional small molecules and monoclonal antibodies toward complex modalities that can engage previously inaccessible biology, overcome resistance and improve drug delivery. These advances create therapeutic opportunities alongside new bioanalytical challenges that influence development strategy, data interpretation and program progression. This webinar explores how emerging therapeutic modalities are reshaping drug development and how effective bioanalytical strategies can help address their unique challenges.
In oncology, antibody-drug conjugates (ADCs) are rapidly evolving beyond single-target, single-payload constructs. Dual-payload ADCs aim to engage complementary cell-killing mechanisms and potentially overcome treatment resistance, while bispecific antibodies can recognize two epitopes or antigens simultaneously. The conjugate landscape also includes degrader-antibody, oligonucleotide-antibody and peptide-antibody conjugates, each introducing unique challenges related to exposure, stability, biotransformation and analyte selection. In parallel, PROTACs and molecular glues are expanding the “undruggable” proteome through targeted degradation of disease-driving proteins, including those associated with c-MYC pathways.
Emerging modalities are also reshaping chronic disease treatment. In autoimmune diseases, peptides and small molecules targeting IL-17, TNF-α, CARD9 and STAT6 may offer oral alternatives to injectable biologics. In obesity, approaches targeting FGF21, GPR61 and related pathways aim to improve gastrointestinal tolerability, lean mass preservation and weight reduction. Targeted protein degradation may also offer new approaches to neurodegenerative diseases, including Parkinson’s, Alzheimer’s, ALS and Huntington’s disease, by removing pathogenic proteins.
As therapeutic modalities become more complex, bioanalysis must evolve with them. Appropriate analyte selection and assays that distinguish intact drug, payload, metabolites, conjugated species or degradation products are essential. This session will examine the scientific principles and practical bioanalytical strategies for emerging modalities, emphasizing LC-MS/MS study-sample analysis.
Register for this webinar to learn how to address bioanalytical challenges associated with emerging therapeutic modalities and strengthen data-driven drug development decisions.
Who Should Attend
This webinar will appeal to:
Bioanalytical & Assay Development Scientists and leaders:
Bioanalytical Sciences, LC-MS/MS, Biomarker Development, PK/PD, Immunogenicity and Analytical Method Development
DMPK, ADME & Clinical Pharmacology teams:
Scientists and leaders responsible for drug exposure, metabolism, pharmacokinetics and interpretation of preclinical and clinical data
Discovery, Translational & Preclinical Scientists
: Researchers developing ADCs, targeted protein degraders, peptides, oligonucleotides and other emerging therapeutic modalities
Drug Development & Outsourcing decision makers:
Directors and Executives in Translational Medicine, Clinical Development, R&D, External Innovation, Strategic Outsourcing and CRO/partner management who determine bioanalytical strategy and select external partners
Register free on Xtalks: https://xtalks.com/webinars/emerging-therapeutic-modalities-and-bioanalytical-strategies/
